| 刘 军,曹苏生,王 伟,李昌文,鹿存涛.不同手术方式联合新辅助化疗治疗乳腺癌患者的临床疗效对比[J].现代生物医学进展英文版,2017,17(24):4751-4754. |
| 不同手术方式联合新辅助化疗治疗乳腺癌患者的临床疗效对比 |
| Comparison of the Clinical Effect of Different Surgical Methods Combined with Neoadjuvant Chemotherapy on Patients with Breast Cancer |
| Received:November 14, 2016 Revised:November 30, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.24.037 |
| 中文关键词: 保乳术 表柔比星 改良根治术 新辅助化疗 乳腺癌 |
| 英文关键词: Breast-conserving surgery Modified radical mastectomy Neoadjuvant chemotherapy Epirubicin Breast cancer |
| 基金项目: |
|
| Hits: 244 |
| Download times: 174 |
| 中文摘要: |
| 摘要 目的：探究不同手术方式联合新辅助化疗治疗乳腺癌患者的临床疗效。方法：选择2012年1月~2014年1月我院收治的80例乳腺癌患者为研究对象。综合考虑患者自主意愿、身体条件、经济状况，将80例乳腺癌患者分为A组(23例)和B组(57例)。两组患者均给予EC(表柔比星+环磷酰胺)方案新辅助化疗，在此基础上A组接受保乳术，B组接受改良根治术。比较两组患者临床疗效、乳房美容效果、生活质量、心理状态。结果：A组患者的住院时间、拔管时间均显著短于B组(P＜0.05)，术中出血量、HAMA、HRSD评分、术后并发症的发生率明显低于B组(P＜0.05)，乳房美容效果明显优于B组(P＜0.05)，QLQ-BR23评分显著高于B组(P＜0.05)。两组患者随访期间的2年生存率、复发率比较差异均无统计学意义(P＞0.05)。结论：保乳术联合表柔比星新辅助化疗治疗乳腺癌的临床效果显著，可减少术后并发症，提高乳房美观度和患者的生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect of different surgical methods combined with Neoadjuvant chemotherapy in treating patients with breast cancer. Methods: 80 patients treated and diagnosed in our hospital from January, 2012 to January, 2014 were enrolled in the present study. According to the willingness, physical condition and financial situation, they were divided them into group A (23 cases) and group B (57 cases). Neoadjuvant chemotherapy of EC regimens (epirubicin+cyclophosphamide) was applied to both groups, on the basis of which, group A received breast-conserving surgery, group B received modified radical mastectomy. The clinical effect, breast cosmetic result, life quality, psychological states were compared in both groups. Results: The operation time, extubation time were significantly shorter than those of group B (p＜0.05), the amount of bleeding, AMA, HRSD score, occurrence rate of complications in group A were significantly lower than those of group B (p＜0.05), the breast cosmetic result of group A was obviously better than that of group B (p＜0.05), and the QLQ-BR23 score in group A was significantly higher than that of group B (p＜0.05). The 2-year survival rate and 2 year recurrence rate showed no statistical difference between the two groups (p＞0.05). Conclusion: Breast-conserving surgery combined with epirubicin neoadjuvant chemotherapy was effective in treating breast cancer, which could decrease the complications, improve the breast cosmetic result and quality of life. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
